BioWorld Asia

Feb. 19, 2003

Oxford GlycoSciences Considers Interest From Celltech, Others

LONDON - Celltech Group plc has refused to comment on reports that it is preparing to make a cash bid for Oxford GlycoSciences plc, undermining the agreed-to all-share takeover offer made by Cambridge Antibody Technology Group plc on Jan. 23. (BioWorld International) Read More

Diatos Raises EUR6.5M Privately To Fund Delivery Technology

Work On Lymphocyte Infection Could Have Implications In HIV

Dolly The Cloned Sheep Opened Research Doors In Biotechnology

Biotech Companies Included In New German Stock Index

SIRTeX Officials Welcome Idea Of $161M Acquisition By Cephalon

Active Biotech Seeks $26.5M In Discounted Rights Offering

Investment Rules Delay First Closing Of New Nordic Fund

Wilex Expands uPA Program Through Deal With San Raffaele

Fees For EMEA Registration Increasing For The First Time

Cerep, Sanofi-Synthélabo Renew Drug Discovery Collaboration

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...